Maria Eugenia Alonso Ferrero
Director Alexion Pharmaceuticals
Methodological and persistent research professional offering broad-based scientific and strategical background in Cell & Gene therapy, Immunomodulation and Immunotherapy. Solid knowledge of Target Discovery/Validation and innovative ATMP development expertise from Discovery to Clinical.
Proven effectiveness in managing, leading and developing top-performing scientific staff and overseeing complex projects in academia and industry.
Seminars
Thursday 26th February 2026
Advancing Lymphodepletion-Free CAR-Ts to Transform Autoimmune Disease Treatment
9:45 am
- Examine how lymphodepletion impacts trial design, patient safety, and overall therapeutic outcomes in autoimmune indications
- Explore strategies to improve monitoring, immunogenicity assessment, and product development for lymphodepletion-free CAR-Ts
- Highlight emerging approaches to optimise persistence and efficacy without reliance on toxic preconditioning regimens
